HBV immune treatment to prevent liver cancer after surgery or transplant
Part of Cancer, Digestive system clinical trials.
This study tests an added hepatitis B immune medicine (HBV immunoglobulin) in people with chronic hepatitis B who have liver cancer and are planning surgery or a liver transplant. The goal is to see if giving this protection around the time of treatment can help prevent liver cancer from coming back or worsening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 19 and 80 years old
- Have chronic hepatitis B and liver cancer, and be planning surgery in at least 6 weeks or be listed for a liver transplant
- Be able to understand the study and its risks, and sign consent before joining
- No other cancer happening at the same time (in addition to liver cancer)
- Not have hepatitis C or HIV infections (hepatitis C antibody alone may be allowed, but hepatitis C virus in blood is not)
- Not be pregnant or breastfeeding; no known allergy to HBV immunoglobulin (HBIG)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests whether a drug called pegylated interferon alpha-2β can help prevent hepatitis B-related liver cancer from coming back after surgery. The drug aims to boost your immune system to fight any remaining cancer cells.
This trial tests a new immune cell therapy (LioCyx-M) for people with advanced liver cancer caused by hepatitis B. It uses specially designed T cells (a type of immune cell) that target the hepatitis B virus and may help fight the cancer.
This Phase 1 study tests a lab-made immune cell treatment that targets hepatitis B (HBV)–related liver cancer. It may help by directing the body’s immune system to attack the cancer, while carefully checking safety.
This study tests a new immune cell therapy (SCG101) for people with a certain type of liver cancer linked to hepatitis B. It's designed for those whose cancer has progressed after standard treatments.
This trial studies an antiviral medicine given after surgery for liver cancer to help prevent the cancer from coming back. It focuses on people who are hepatitis B–positive (HBsAg positive) and have complete remission on follow-up checks.
This trial tests lab-made immune T cells that target hepatitis B (HBV) using a treatment called LioCyx-M, either alone or with lenvatinib. It’s for people with advanced HBV-related hepatocellular carcinoma (liver cancer) who can’t be cured with surgery or local procedures.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.